DIANA

• Kraj:Polska
• : Język.:polski
• : Utworzony.: 30-12-17
• : Ostatnie Logowanie.: 16-03-22

×

: Kontakt.

: Imię.

: E-mail.

: Wiadomość.

Proszę zamienić znaczniki %d na własne liczby

: Dodaj.

Wiadomość nie może być pusta!

Wiadomość zostanie przetłumaczona po wysłaniu (jeżeli środki są wystarczające)

: Captcha. Kod Ochronny.

Załączniki:

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

Ilość dopuszczalnych plików: 5

JPEG, JPG, PNG, GIF, DOC, PDF, ZIP, RAR, TAR, HTML, SWF, TXT, XLS, DOCX, XLSX : lub : ODT : tylko formaty:.

: Maksymalny rozmiar pliku. 3MB.

: Wyślij Wiadomość.

moderna, curevac, covid-19, coronavirus, katemera: mgwirizano wapagulu ndi anthu wamba,

: Opis.: BioNTech, moderna, curevac, covid-19, coronavirus, katemera: 20200320AD BTM Innovations, mgwirizano wapagulu ndi anthu wamba, Apeiron, SRI International, Iktos, mankhwala oletsa kubereka, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, Mu Marichi 16, European Commission idalengeza kuti idapereka EUR 80 miliyoni kuthandiza kampani yaku Germany CureVac kuti ipititse patsogolo ntchito ya katemera wa coronavirus. Izi zikuwoneka tsiku lomwe magwero aboma aku Germany ati boma la a Donald Trump likuyang'ana njira yomwe ingapezere katemerayu. Kodi izi zikutanthauza kuti pali kampani imodzi yokha yomwe ikugwiritsa ntchito yankho lomwe ndilofunika kwambiri kwa anthu? WHO (World Health Organisation) imasindikiza zambiri pamakampani 13 otero pamasamba ake, ndipo database ya Global Data ikuwonetsa mabungwe 30 omwe akugwira ntchito pamutuwu. Kodi pali mwayi wina wowerengera yankho ku mavuto athu? Mdierekezi amakhala mu tsatanetsatane. Akuluakulu, pali kampani imodzi yokha - American Moderna - yomwe idutsa gawo loyeserera kuchipatala komwe katemera amayesedwa mwa anthu. Ziyeso zimachitika ku United States ku Washington Institute of Health Research ku Seattle. Kukula msanga kwa katemera wotereyu sikunachitike ndipo kunali kotheka chifukwa asayansi amatha kugwiritsa ntchito zomwe akukumana nazo chifukwa cha zovuta zina za SARS ndi MERS. Ngakhale ntchito yophwanya mbiri, ngakhale ngati katemera akhale wotetezeka komanso wogwira pakulimbana ndi kachilomboka, sichipezeka pafupifupi chaka chimodzi. Osewera ena onse omwe akufuna kupanga katemera wa coronavirus pakadali pano ali pagawo lotsogola kwambiri. Gawo loyambirira ndi kafukufuku mu labotale ndi zinyama zomwe zingangotulutsa katemera pafupifupi chaka ndi theka. Ndizovuta kunena kuti ndani amapambana katemera wa katemerayu, koma mwayi wawukulu kwambiri si poyambira, koma makampani akuluakulu azamankhwala. Kampani ya ku Germany CureVac imagwirizana ndi gulu la anthu onse ku Oslo, otchedwa Coalition for Epidemic Kukonzekera (CEPI). Akugwira ntchito ya katemera wa mRNA. Monga chimphona chachikulu cha ku America cha Moderna mRNA, CureVac ikufuna kutsimikizira kuti katemera wa mRNA apangidwa ndikupanga mofulumira kuposa katemera wachikhalidwe, ndipo akufuna kupita ku mayeso azachipatala a Phase I koyambirira kwa chilimwe. Monga CureVac - kampani yaku Germany ya BioNTech, yomwe imapanga katemera wa mRNA wa khansa ndi fuluwenza - ndiye mutu wothandizirana ndi Pfizer wamkulu wa mankhwala kuti apange katemera wolimbana ndi kachilombo ka Covid19. Sanofi ndi Janssen amagwirizana ndi American Biomedical Advanced Office for Research and Development (BARDA) ndipo nawonso ali pachiwopsezo. Ntchito zing'onozing'ono zambiri zikuchitikanso. Pa Lolemba2 EUR 7 miliyoni zothandizidwa pansi pa pulogalamu ya Horizon2020 zidaperekedwa kwa mabungwe azamayokha a Danish: makampani a biotechnology ExpreS2ion Biotechnologies ndi AdaptVac. Consortium ikufuna kukhazikitsa kuyesa kwachipatala kwa gawo la I / IIa pakadutsa miyezi 12. Ngakhale kuti katemera koyambirira amatha kukhala gawo loyambirira mpaka chilimwe, olamulira angafunike kuyesedwa kwa zaka ziwiri kapena chimodzi kuti atsimikizire kuti katemera ali bwino. Pambuyo povomerezedwa, makampani amatha kuyamba kupanga ndikugawa katemera pamsika wamalonda, zomwe zimatengeranso nthawi yayitali. Mwachidule, dziko limawona katemera wovomerezeka wa Covid-19 kokha pakati pa 2121. Komabe, likukwaniritsidwa kuti katemera si chipulumutso chokha. Makampani ambiri amayembekeza kupanga mankhwala atsopano osokoneza bongo kapena kusinthitsa mankhwala omwe akuyesa kulimbana ndi kachilomboka. Ili ndi ntchito yovuta chifukwa, mosiyana ndi mabakiteriya, ma virus amabisala mu maselo athu. Izi zikutanthauza kuti mankhwala omwe amayimitsa kachilomboka nthawi zambiri amakhudza maselo athu, omwe amatha kuyambitsa mavuto. Kampani ya Parisian Iktos yomwe ikugwira ntchito yopanga mankhwala pogwiritsa ntchito nzeru zopanga inayamba mgwirizano ndi kampani ya US SRI International. Cholinga cha mgwirizanowu ndikupanga mankhwala atsopano opatsirana pogwiritsira ntchito Covid19 ndi mitundu ina ya ma virus. Kampani yaku Austria biotechnology Apeiron idayamba kuyesa kwachiwiri kwa oyeserera achipatala motsutsana ndi Covid-19 kumapeto kwa February. Mankhwala a protein adamaliza kale maphunziro a Phase I ndi II pakuchiza kuvulala kwam'mapapo ndipo akuyembekezeka kugwira ntchito poyesa mapuloteni omwe coronavirus imamangirira panthawi yolowa m'mapapo. palinso mapulojekiti ambiri omwe cholinga chawo ndikusintha kugwiritsa ntchito mankhwala ovomerezeka a mankhwalawa pochiza Covid-19. Izi zili ndi mwayi kuti chitetezo cha mankhwalawo chimadziwika kale ndipo chitha kufikira msika mwachangu. Ofufuzawo ochokera ku Göttingen ndi Berlin, Germany, akufufuzira kuthekera kwa kamostat mesylate - mankhwala ovomerezeka ku Japan pochiza matenda a kapamba. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

javno-privatno partnerstvo, Apeiron, SRI International, Iktos, antivirusni lijekovi, curevac, covid-19, koronavirus, cjepivo:

: Opis.: BioNTech, moderna, curevac, covid-19, koronavirus, cjepivo: 20200320AD BTM inovacije, javno-privatno partnerstvo, Apeiron, SRI International, Iktos, antivirusni lijekovi, AdaptVac, ExpreS2ion biotehnologije, pfizer, janssen, sanofi, Europska komisija je 16. ožujka objavila da je ponudila 80 milijuna eura za podršku njemačkoj tvrtki CureVac za ubrzanje rada na cjepivu protiv koronavirusa. Te se informacije pojavljuju dan nakon što su njemački vladini izvori rekli da je uprava Donalda Trumpa tražila način da se pristupi ovom potencijalnom cjepivu. Znači li to da postoji samo jedna tvrtka koja radi na rješenju koje je toliko važno za čovječanstvo? WHO (Svjetska zdravstvena organizacija) na svojim web stranicama objavljuje podatke o 13 takvih tvrtki, a baza podataka Global Data pokazuje 30 institucija koje rade na ovoj temi. Dakle, postoje li šanse za brzi lijek za naše probleme? Đavo je uvijek u detaljima. Službeno, postoji samo jedna tvrtka - američka Moderna - koja je prošla fazu kliničkog ispitivanja gdje se cjepivo testira na ljudima. Testovi se provode u Sjedinjenim Državama na Washingtonskom institutu za zdravstvena istraživanja u Seattlu. Ovakav brzi razvoj potencijalnog cjepiva bez presedana je i bio moguć jer su znanstvenici mogli iskoristiti iskustvo s koronavirusima koji su uzrokovali epidemiju SARS-a i MERS-a. Unatoč rekordnom radu, čak i ako se cjepivo pokaže sigurnim i učinkovitim protiv virusa, neće biti na raspolaganju najmanje godinu dana. Svi ostali igrači koji žele razviti cjepivo protiv koronavirusa trenutno su u najnaprednijoj pretkliničkoj fazi. Predklinička faza je istraživanje u laboratorijima i životinjama koje mogu dovesti do cijepljenja tek za godinu i pol. Teško je reći tko pobjeđuje u utrci za cjepivo, ali najveće šanse nisu startapovi, već velike farmaceutske tvrtke. Njemačka tvrtka CureVac surađuje s javnom institucijom sa sjedištem u Oslu, tzv Koalicija za pripremljenost epidemije (CEPI). Rade na cjepivu zasnovanom na mRNA. Poput američke gigante Moderne mRNA, CureVac želi dokazati da će se mRNA cjepiva razviti i proizvesti brže od tradicionalnih cjepiva, te namjerava krenuti u klinička ispitivanja faze I početkom ovog ljeta. Kao i CureVac - njemačka tvrtka BioNTech, koja razvija mRNA cjepiva protiv raka i gripe - predmet je potencijalnog partnerstva s farmaceutskim gigantom Pfizer-om radi razvoja cjepiva protiv virusa Covid19. Sanofi i Janssen surađuju s Američkim naprednim uredom za istraživanje i razvoj (BARDA), a također su u pretkliničkoj fazi. U tijeku je i mnogo manjih projekata. U ponedjeljak je danskom javno-privatnom konzorciju dodijeljeno 7 milijuna eura subvencija u okviru programa Horizon2020: biotehnološke tvrtke ExpreS2ion Biotechnologies i AdaptVac. Konzorcij namjerava započeti kliničko ispitivanje faze I / IIa za cjepivo u roku od 12 mjeseci. Iako će najstarija cjepiva biti u pretkliničkoj fazi do ljeta, regulatorima će vjerojatno trebati jedna do dvije godine ispitivanja na ljudima kako bi osigurali da je cjepivo sigurno i učinkovito. Nakon dobivanja odobrenja, tvrtke mogu započeti s proizvodnjom i distribucijom cjepiva u komercijalnom obimu, što također traje dugo vremena. Ukratko, svijet vidi odobreno cjepivo protiv Covid-19 tek oko sredine 2121. godine. Međutim, ispada da cjepivo nije jedini spas. Mnoge tvrtke očekuju da će razviti nove antivirusne lijekove ili prilagoditi trenutne eksperimentalne lijekove za borbu protiv novog virusa. Ovo je težak zadatak, jer se za razliku od bakterija virusi skrivaju u našim vlastitim stanicama. To znači da lijekovi koji zaustavljaju virus češće utječu na naše stanice, što može izazvati nuspojave. Pariška tvrtka Iktos koja se bavi proizvodnjom lijekova umjetnom inteligencijom započela je suradnju s američkom kemijskom tvrtkom SRI International. Cilj suradnje je razviti nove antivirusne lijekove za liječenje Covid19 i drugih vrsta virusa. Austrijska biotehnološka tvrtka Apeiron započela je krajem veljače pilot-kliničko ispitivanje lijeka kandidata protiv Covid-19. Proteinski lijek je već završio studije faze I i II u liječenju akutnih ozljeda pluća i očekuje se da će djelovati oponašajući protein s kojim se koronavirus veže tijekom invazije pluća. postoji i mnogo projekata usmjerenih na promjenu uporabe odobrenih antivirusnih lijekova u liječenju Covid-19. To ima tu prednost što je sigurnost lijeka već poznata i može brže stići na tržište. Istraživači iz Göttingena i Berlina u Njemačkoj trenutno istražuju potencijal kamostat mezilata - lijeka koji je u Japanu odobren za liječenje pankreatitisa. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

公私合作夥伴關係，Apeiron，SRI International，Iktos，抗病毒藥，AdaptVac，冠狀病毒，疫苗：

: Opis.: BioNTech，Moderna，Curevac，covid-19，冠狀病毒，疫苗： 20200320AD BTM Innovations，公私合作夥伴關係，Apeiron，SRI International，Iktos，抗病毒藥，AdaptVac，ExpreS2ion Biotechnologies，pfizer，janssen，sanofi， 3月16日，歐盟委員會宣布將提供8000萬歐元，以支持德國公司CureVac加快冠狀病毒疫苗的研發工作。該信息出現在德國政府消息人士稱唐納德·特朗普政府正在尋找一種途徑獲得這種潛在疫苗的第二天。這是否意味著只有一家公司正在研究對人類如此重要的解決方案？世衛組織（世界衛生組織）在其網站上發布了13家此類公司的數據，全球數據數據庫顯示有30家從事該主題的機構。那麼，是否有機會迅速解決我們的麻煩？魔鬼永遠在細節中。 正式地，只有一家公司-American Moderna-經歷了在人體中進行疫苗測試的臨床試驗階段。測試是在美國西雅圖的華盛頓健康研究所進行的。如此快速的潛在疫苗開發是空前的，而且是可能的，因為科學家可以利用冠狀病毒的經驗來引發SARS和MERS流行。儘管有破紀錄的工作，即使疫苗證明對這種病毒是安全有效的，也將至少有一年不可用。 其他所有想要開發冠狀病毒疫苗的參與者目前都處於臨床前階段。臨床前階段是在實驗室和動物中進行的研究，這些研究只能在大約一年半的時間內進行疫苗接種。很難說誰贏得了疫苗競賽，但是最大的機會不是初創企業，而是大型製藥公司。 德國公司CureVac與位於奧斯陸的一家公共機構合作，所謂的流行病預防聯盟（CEPI）。他們正在研究一種基於mRNA的疫苗。與美國巨頭Moderna mRNA一樣，CureVac希望證明mRNA疫苗的開發和生產速度要比傳統疫苗更快，並打算在今年夏天初進行I期臨床試驗。 像CureVac一樣，德國公司BioNTech專門開發針對癌症和流感的mRNA疫苗，也是與製藥巨頭輝瑞公司潛在合作夥伴關係的對象，以開發針對Covid19病毒的疫苗。賽諾菲（Sanofi）和揚森（Janssen）與美國生物醫學高級研究與開發辦公室（BARDA）合作，並且也處於臨床前階段。 許多較小的項目也在進行中。 2月2日，“地平線2020”計劃下的700萬歐元補貼分配給了丹麥的公私合營企業：生物技術公司ExpreS2ion Biotechnologies和AdaptVac。該聯盟計劃在12個月內針對該疫苗啟動I / IIa期臨床試驗。 儘管最早的疫苗可能在夏季之前都處於臨床前階段，但監管機構可能需要進行一到兩年的人工測試，以確保疫苗安全有效。獲得批准後，公司可以開始以商業規模生產和分發疫苗，這也需要很長時間。總而言之，全世界僅在2121年中左右才看到批准的Covid-19疫苗。 然而，事實證明，疫苗不是唯一的救贖方法。許多公司期望開發新的抗病毒藥物或使當前的實驗藥物適應新病毒。這是一項艱鉅的任務，因為與細菌不同，病毒隱藏在我們自己的細胞中。這意味著阻止病毒的藥物會更多地影響我們的細胞，從而引起副作用。 從事人工智能生產藥物的巴黎公司Iktos開始與美國化學公司SRI International合作。合作的目標是開發新的抗病毒藥物來治療Covid19和其他類型的病毒。奧地利生物技術公司Apeiron於2月底開始了針對Covid-19的候選藥物的II期中試臨床試驗。該蛋白藥物已經完成了急性肺損傷治療的I和II期研究，有望通過模仿在肺部入侵過程中與冠狀病毒結合的蛋白來發揮作用。還有許多項目旨在改變批准的抗病毒藥物在治療Covid-19中的用途。這樣做的好處是，藥物的安全性是已知的，可以更快地進入市場。來自哥廷根和德國柏林的研究人員目前正在研究甲磺酸鉀敏酯的潛力。甲磺酸鉀敏酯是一種在日本獲准用於治療胰腺炎的藥物。 http：//www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25

BioNTech，Moderna，Curevac，covid-19，冠状病毒，疫苗：公私合作伙伴关系，

: Opis.: BioNTech，Moderna，Curevac，covid-19，冠状病毒，疫苗： 20200320AD BTM Innovations，公私合作伙伴关系，Apeiron，SRI International，Iktos，抗病毒药，AdaptVac，ExpreS2ion Biotechnologies，pfizer，janssen，sanofi， 3月16日，欧盟委员会宣布将提供8000万欧元，以支持德国公司CureVac加快冠状病毒疫苗的研发工作。该信息出现在德国政府消息人士称唐纳德·特朗普政府正在寻找一种途径获得这种潜在疫苗的第二天。这是否意味着只有一家公司正在研究对人类如此重要的解决方案？世卫组织（世界卫生组织）在其网站上发布了13家此类公司的数据，全球数据数据库显示有30家从事该主题的机构。那么，是否有机会迅速解决我们的麻烦？魔鬼永远在细节中。 正式地，只有一家公司-American Moderna-经历了在人体中进行疫苗测试的临床试验阶段。测试是在美国西雅图的华盛顿健康研究所进行的。如此快速的潜在疫苗开发是空前的，而且是可能的，因为科学家可以利用冠状病毒的经验来引发SARS和MERS流行。尽管有破纪录的工作，即使疫苗证明对这种病毒是安全有效的，也将至少有一年不可用。 其他所有想要开发冠状病毒疫苗的参与者目前都处于临床前阶段。临床前阶段是在实验室和动物中进行的研究，这些研究只能在大约一年半的时间内进行疫苗接种。很难说谁赢得了疫苗竞赛，但是最大的机会不是初创企业，而是大型制药公司。 德国公司CureVac与位于奥斯陆的一家公共机构合作，所谓的流行病预防联盟（CEPI）。他们正在研究一种基于mRNA的疫苗。与美国巨头Moderna mRNA一样，CureVac希望证明mRNA疫苗的开发和生产速度要比传统疫苗更快，并打算在今年夏天初进行I期临床试验。 像CureVac一样，德国公司BioNTech专门开发用于癌症和流感的mRNA疫苗，也是与制药巨头辉瑞公司潜在合作伙伴关系的对象，以开发针对Covid19病毒的疫苗。赛诺菲（Sanofi）和扬森（Janssen）与美国生物医学高级研究与开发办公室（BARDA）合作，并且也处于临床前阶段。 许多较小的项目也在进行中。 2月2日，“地平线2020”计划下的700万欧元补贴分配给了丹麦的公私合营企业：生物技术公司ExpreS2ion Biotechnologies和AdaptVac。该联盟计划在12个月内针对该疫苗启动I / IIa期临床试验。 尽管最早的疫苗可能在夏季之前都处于临床前阶段，但监管机构可能需要进行一到两年的人工测试，以确保疫苗安全有效。获得批准后，公司可以开始以商业规模生产和分发疫苗，这也需要很长时间。总而言之，全世界仅在2121年中左右才看到批准的Covid-19疫苗。 然而，事实证明，疫苗不是唯一的救赎方法。许多公司期望开发新的抗病毒药物或使当前的实验药物适应新病毒。这是一项艰巨的任务，因为与细菌不同，病毒隐藏在我们自己的细胞中。这意味着阻止病毒的药物会更多地影响我们的细胞，从而引起副作用。 从事人工智能生产药物的巴黎公司Iktos开始与美国化学公司SRI International合作。合作的目标是开发新的抗病毒药物来治疗Covid19和其他类型的病毒。奥地利生物技术公司Apeiron于2月底开始了针对Covid-19的候选药物的II期中试临床试验。该蛋白药物已经完成了急性肺损伤治疗的I和II期研究，有望通过模仿在肺部入侵过程中与冠状病毒结合的蛋白来发挥作用。还有许多项目旨在改变批准的抗病毒药物在治疗Covid-19中的用途。这样做的好处是，药物的安全性是已知的，可以更快地进入市场。来自哥廷根和德国柏林的研究人员目前正在研究甲磺酸钾敏酯的潜力。甲磺酸钾敏酯是一种在日本获准用于治疗胰腺炎的药物。 http：//www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 26-11-25